License and Collaboration Agreements - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		9 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Sep. 30, 2021	Dec. 31, 2021	Oct. 31, 2018
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Product revenues, net	$ 211,237	$ 141,839	$ 400,062	$ 266,765
Settlement charge	0	0	0	10,000
Research, option and milestone expense	6,000	3,000	6,000	3,000
Up-front and development milestone expenses	8,800		8,800
Henogen SA [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Research and development expenses charges	17,100
Collaborative Arrangement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payment for option exercise			187,100
Stock options exercised or expired
Development Milestone and Upfront Fee Recognized as Research and Development Expense	31,700		45,700
Collaborative Arrangement | Maximum [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contingent research milestone payments			7,000
Development Milestone and Settlement Upfront Fee Recognized as Research and Development Expense	3,700,000		3,700,000
Collaborative Arrangement | Roche Holding A.G. [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Product revenues, net	22,300	44,300	22,300	44,300
Deferred Revenue	619,200		619,200
Deferred Revenue, Current	89,200		89,200
Deferred Revenue Separate Material Options Right	485,000		485,000			$ 485,000
Research and development expense	26,400	$ 18,000	44,100	$ 31,400
Collaboration Receivable	26,400		$ 26,400
Equity Investment Agreement [Member] | Lysogene S.A. [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Development, regulatory and sales milestones payments to be paid							$ 102,800
Common stock purchased,shares			1,140,728
Equity Investment Agreement [Member] | Lysogene S.A. [Member] | Other Noncurrent Assets [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Equity investment publicly traded security	$ 800		$ 800